Skip to main content

Table 1 Gedatolisib partially reversed ABCB1-medaited MDR

From: ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells

Drug

IC50 ± SD(RF)

SW620 (μM)

SW620/ADR (μΜ)

Doxorubicin

0.042 ± 0.009 (1.00)

10.653 ± 0.600 (253.64)

+ Gedatolisib (0.1 μM)

0.043 ± 0.009 (1.024)

9.767 ± 0.424 (232.55)

+ Gedatolisib (0.2 μM)

0.039 ± 0.010 (0.928)

6.431 ± 0.041 (153.12)*

+ Verapamil (1 μM)

0.038 ± 0.007 (0.905)

0.412 ± 0.030 (9.80)*

Paclitaxel

0.038 ± 0.005 (1.00)

5.422 ± 0.556 (142.68)

+ Gedatolisib (0.1 μM)

0.040 ± 0.004 (1.05)

4.379 ± 0.234 (115.24)*

+ Gedatolisib (0.2 μM)

0.037 ± 0.006 (0.97)

3.273 ± 0.121 (86.13)*

+ Verapamil (1 μM)

0.042 ± 0.004 (1.10)

0.090 ± 0.082 (2.37)*

Vincristine

0.098 ± 0.009 (1.00)

12.472 ± 1.263 (127.27)

+ Gedatolisib (0.1 μM)

0.088 ± 0.008 (0.90)

10.863 ± 1.463 (110.85)*

+ Gedatolisib (0.2 μM)

0.091 ± 0.009 (0.93)

5.324 ± 0.561 (54.33)*

+ Verapamil (1 μM)

0.087 ± 0.009 (0.89)

0.231 ± 0.042 (2.36)*

Cisplatin

3.234 ± 0.194 (1.00)

3.536 ± 0.211 (1.09)

+ Gedatolisib (0.1 μM)

3.354 ± 0.213 (1.04)

3.743 ± 0.263 (1.13)

+ Gedatolisib (0.2 μM)

3.453 ± 0.253 (1.07)

3.243 ± 0.373 (0.8)

+ Verapamil (1 μM)

3.244 ± 0.210 (1.00)

3.543 ± 0.262 (1.07)

  1. Resistance fold (RF) was calculated from dividing the IC50 values of SW620/ADR cells by the IC50 values of SW620 cells in the presence or absence of gedatolisib or verapamil
  2. *Presents when p value is < 0.05. Data was showed with mean ± SD, which is representative for at least three independent experiments